Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2

Journal of Neuroscience Research

Volumn 93, Issue 10, 2015, Pages 1567-1580

  Hamm, Matthew ^a   Bailey, Rachel ^a   Shaw, Gerry ^b   Yen, Shu Hui ^c   Lewis, Jada ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b EnCor Biotechnology Inc   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

AB_2100313; AB_223647; AB_223651; AB_2315150; AB_2492290; AB_2492292; AB_2492293; AB_2492294; AB_304676; AB_771432; Leucine rich repeat kinase 2; Parkinson's disease; Rid_000081; Tau

Indexed keywords

BETA TUBULIN; DIVALENT CATION; EPITOPE; LEUCINE RICH REPEAT KINASE 2; MAGNESIUM; MAGNESIUM ION; TAU PROTEIN; GLYCINE; LRRK2 PROTEIN, HUMAN; MANGANESE; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; SERINE; THREONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CATALYSIS; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IN VITRO STUDY; MICROTUBULE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN POLYMERIZATION; PROTEIN PROTEIN INTERACTION; TAUOPATHY; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUTATION; PHOSPHORYLATION;

ANIMALS; ANTIBODY SPECIFICITY; GLYCINE; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MANGANESE; MUTATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SERINE; TAU PROTEINS; THREONINE;

EID: 84939467302     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23614     Document Type: Article

References (29)

1. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. 2002. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103:26-35.
2. Bailey RM, Covy JP, Melrose HL, Rousseau L, Watkinson R, Knight J, Miles S, Farrer MJ, Dickson DW, Giasson BI. 2013. LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol 126:809-827.
3. Berg D, Schweitzer KJ, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brüssel T, Schulte C, Maass S, Nägele T. 2005. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain J Neurol 128:3000-3011.
4. Caesar M, Zach S, Carlson CB, Brockmann K, Gasser T, Gillardon F. 2013. Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Neurobiol Dis 54:280-288.
5. Covy JP, Giasson BI. 2010. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition. J Neurochem 115:36-46.
6. Crowe A, Ksiezak-Reding H, Liu WK, Dickson DW, Yen SH. 1991. The N terminal region of human tau is present in Alzheimer's disease protein A68 and is incorporated into paired helical filaments. Am J Pathol 139:1463-1470.
7. Dächsel JC, Farrer MJ. 2010. LRRK2 and Parkinson disease. Arch Neurol 67:542-547.
8. Dolan PJ, Johnson GVW. 2010. The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel 13:595-603.
9. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. 1992. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141-1154.
10. Gillardon F. 2009. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J Neurochem 110:1514-1522.
11. Goedert M, Jakes R, Vanmechelen E. 1995. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 189:167-169.
12. Hanger DP, Anderton BH, Noble W. 2009. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112-119.
13. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller BI, Geschwind DH, Bird TD, McKeel D, Goate A. 1998. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914-1917.
14. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. 2003. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62:389-397.
15. Kar S, Fan J, Smith MJ, Goedert M, Amos LA. 2003. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J 22:70-77.
16. Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, Maruyama H, Ichikawa T, Obata F. 2012. LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PloS One 7:e30834.
17. Klein C, Kramer EM, Cardine AM, Schraven B, Brandt R, Trotter J. 2002. Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau. J Neurosci 22:698-707.
18. Lovitt B, Vanderporten EC, Sheng Z, Zhu H, Drummond J, Liu Y. 2010. Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). Biochemistry 49:3092-3100.
19. Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH, Brown H, Tiwari A, Hayward L. 2009. Axonal transport defects in neurodegenerative diseases. J Neurosci 29:12776-12786.
20. Noble W, Hanger DP, Miller CCJ, Lovestone S. 2013. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 4:83.
21. Papasozomenos SC, Binder LI. 1987. Phosphorylation determines two distinct species of tau in the central nervous system. Cell Motil Cytoskel 8:210-226.
22. Poulopoulos M, Levy OA, Alcalay RN. 2012. The neuropathology of genetic Parkinson's disease. Mov Disord 27:831-842.
23. Samsonov A, Yu JZ, Rasenick M, Popov SV. 2004. Tau interaction with microtubules in vivo. J Cell Sci 117:6129-6141.
24. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E. 1995. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell 6:1887-1902.
25. Vermersch P, Frigard B, Davi JP, Fallet-Bianco C, Delacourte A. 1992. Presence of abnormally phosphorylated tau proteins in the entorhinal cortex of aged nondemented subjects. Neurosci Lett 144:143-146.
26. Vermersch P, Delacourte A, Javoy-Agid F, Hauw JJ, Agid Y. 1993. Dementia in Parkinson's disease: biochemical evidence for cortical involvement using the immunodetection of abnormal tau proteins. Ann Neurol 33:445-450.
27. West AB, Moore, DJ, Biskup S, Bugayenko A, Smith WW, Ross, CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102:16842-16847.
28. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL. 2007. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16:223-232.
29. Zimprich A, Biskup S, Leitne, P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607.